NT5C1A and dermatomyositis: The relationship between seropositivity for anti‐NT5C1A antibody and other clinicopathologic features in IBM or dermatomyositis have been discussed and some report that seropositivity for anti‐NT5C1A antibody in IBM or juvenile myositis predict a more severe phenotype.4, 10, 11